MSA Trust

Introduction

<div class="infobox infobox-institution">
{| class="infobox-table"
| colspan="2" class="infobox-header" | MSA Trust
|-
| Founded | 1969 (as MSA Association)
|-
| Headquarters | London, United Kingdom
|-
| Type | Non-profit Medical Research Charity
|-
| Focus | Multiple system atrophy research, support, education
|-
| Annual Research Funding | £500,000-800,000 (2023-2024)
|-
| Website | [msatrust.org.uk](https://www.msatrust.org.uk)
|}
</div>

The MSA Trust is the UK's leading charity dedicated to [multiple system atrophy](/diseases/multiple-system-atrophy) (MSA), a rare and rapidly progressive neurodegenerative disorder[@msa]. Founded in 1969 as the MSA Association, the organization has been supporting people with MSA and funding research into the condition for over 55 years. The Trust serves as the primary source of information, support, and advocacy for the MSA community in the United Kingdom and internationally.

MSA is characterized by a combination of symptoms affecting autonomic functions (blood pressure, bladder, digestion), movement (Parkinsonism), and coordination (ataxia). The disease involves degeneration of multiple brain systems, including the basal ganglia, cerebellum, and autonomic nervous system[@fanciulli2023]. With a prevalence of approximately 1.9-4.9 per 100,000 individuals, MSA represents one of the rarer neurodegenerative movement disorders, yet its impact on patients and families is devastating due to the rapid progression and limited treatment options[@koga2020].

Mission and Vision

Introduction

<div class="infobox infobox-institution">
{| class="infobox-table"
| colspan="2" class="infobox-header" | MSA Trust
|-
| Founded | 1969 (as MSA Association)
|-
| Headquarters | London, United Kingdom
|-
| Type | Non-profit Medical Research Charity
|-
| Focus | Multiple system atrophy research, support, education
|-
| Annual Research Funding | £500,000-800,000 (2023-2024)
|-
| Website | [msatrust.org.uk](https://www.msatrust.org.uk)
|}
</div>

The MSA Trust is the UK's leading charity dedicated to [multiple system atrophy](/diseases/multiple-system-atrophy) (MSA), a rare and rapidly progressive neurodegenerative disorder[@msa]. Founded in 1969 as the MSA Association, the organization has been supporting people with MSA and funding research into the condition for over 55 years. The Trust serves as the primary source of information, support, and advocacy for the MSA community in the United Kingdom and internationally.

MSA is characterized by a combination of symptoms affecting autonomic functions (blood pressure, bladder, digestion), movement (Parkinsonism), and coordination (ataxia). The disease involves degeneration of multiple brain systems, including the basal ganglia, cerebellum, and autonomic nervous system[@fanciulli2023]. With a prevalence of approximately 1.9-4.9 per 100,000 individuals, MSA represents one of the rarer neurodegenerative movement disorders, yet its impact on patients and families is devastating due to the rapid progression and limited treatment options[@koga2020].

Mission and Vision

Mission Statement

The MSA Trust is committed to:

Strategic Priorities (2024-2027)

The Trust's current strategic plan focuses on four key areas:

• Research Acceleration: Identifying and funding the most promising research projects with potential for clinical translation
• Support Services Enhancement: Expanding and improving support services for the MSA community
• Healthcare Professional Education: Training healthcare professionals to better understand and manage MSA
• International Collaboration: Working with international partners to advance MSA research and care

About Multiple System Atrophy

Types of MSA

MSA is classified into three main variants[@wenning2020]:

• MSA-P (Parkinsonian Type): Predominant parkinsonism features including rigidity, bradykinesia, and tremor. This variant accounts for approximately 60-70% of cases in Western populations.
• MSA-C (Cerebellar Type): Predominant cerebellar/cerebellar ataxia features including gait instability, limb incoordination, and oculomotor abnormalities. This variant is more common in Asian populations.
• Mixed Type: Features of both P and C types, presenting with combined parkinsonian and cerebellar symptoms.

Key Symptoms

The clinical presentation of MSA involves multiple system involvement[@fanciulli2019]:

Autonomic Dysfunction:

• Orthostatic hypotension (drop in blood pressure upon standing)
• Urinary dysfunction (urgency, frequency, retention)
• Gastrointestinal issues (constipation, dysphagia)
• Sexual dysfunction
• Excessive sweating or anhidrosis

• Rigidity (stiffness)
• Bradykinesia (slowness of movement)
• Tremor (postural or resting)
• Gait instability
• Early postural instability

• Ataxia (coordination difficulties)
• Dysarthria (speech difficulty)
• Nystagmus (involuntary eye movements)

• REM sleep behavior disorder
• Cognitive changes (executive dysfunction in later stages)
• Pain syndromes

Pathophysiology

MSA is classified as an α-synucleinopathy, sharing pathological features with Parkinson's disease but with distinct characteristics[@jellinger2021]:

Challenges in MSA Care

• Diagnostic Delay: Often misdiagnosed as Parkinson's disease, leading to delayed appropriate care
• Rapid Progression: Median survival of 6-10 years from symptom onset
• Limited Treatment Options: No disease-modifying therapies currently available
• Multidisciplinary Care Needs: Requires coordinated care from neurologists, urologists, cardiologists, and other specialists

Research Programs

Research Focus Areas

The MSA Trust funds research across multiple domains[@sanchezmendoza2023]:

1. Alpha-Synuclein Biology

• Mechanisms of α-synuclein misfolding and aggregation
• Propagation of pathological α-synuclein in the brain
• Strain-specific differences between MSA and Parkinson's disease α-synuclein

2. Biomarker Development

• Fluid biomarkers (blood, CSF)
• Imaging biomarkers (MRI, PET)
• Clinical biomarkers (autonomic function tests)

3. Neuroprotection and Disease Modification

• Neuroprotective compounds
• Oligodendrocyte function restoration
• Synaptic protection

4. Clinical Trials

• Patient recruitment support
• Trial site preparation
• Patient and family engagement

Research Funding Mechanisms

Project Grants:

• Duration: 1-3 years
• Amount: £50,000-250,000
• Focus: Specific research questions with clear hypotheses

• Support for early-career researchers
• Clinical and basic science tracks
• Mentorship programs

• Small grants for preliminary data collection
• Feasibility studies
• Novel technique development

International Research Partnerships

The MSA Trust collaborates with:

• MSA Alliance: International consortium of MSA organizations
• European MSA Study Group (EMSA-SG): Pan-European research network
• Multiple System Atrophy Research Foundation: US-based research funding organization
• Michael J. Fox Foundation: Parkinson's and related synucleinopathy research

Pathophysiology Research

MSA is characterized by a distinctive neuropathology:

Alpha-Synuclein Pathology

The hallmark of MSA is abnormal [alpha-synuclein](/proteins/alpha-synuclein) aggregation in oligodendrocytes [@koga2020]:

• Glial Cytoplasmic Inclusions (GCIs): Primary pathological feature
• Oligodendroglial Dysfunction: Myelin-producing cells are primarily affected [@kimbrough2023]
• Strain Variation: Distinct alpha-synuclein strains from PD [@valera2022]
• Propagation: Spreading mechanisms through neural circuits

Neuropathological Features

• Basal Degeneration: Involvement of putamen, caudate, and substantia nigra
• Cerebellar Atrophy: Purkinje cell loss, pontine and cerebellar involvement
• Autonomic Nuclei: Degeneration of vagal nuclei, Onuf's nucleus
• White Matter Changes: Demyelination and axonal loss [@krismer2022]

Clinical Research

Biomarker Development

Current research focuses on [@ippolito2022]:

• Neuroimaging: MRI markers for differential diagnosis
• CSF Biomarkers: Alpha-synuclein species in cerebrospinal fluid
• Autonomic Testing: Quantitative autonomic function tests
• Skin Biopsies: Detection of peripheral alpha-synuclein

Clinical Trials

The Trust supports numerous clinical trials:

• Neuroprotective Agents: Drugs to slow disease progression
• Symptomatic Treatments: Motor and autonomic symptom management
• Disease-Modifying Therapies: Targeting underlying pathology
• Co-enzyme Q10: High-dose ubiquinol trials [@perezsoriano2023]

Genetics of MSA

Recent genetic studies have identified risk factors [@sanchezmendoza2023]:

• COQ2: Mutations associated with MSA risk
• SNCA: Alpha-synuclein gene variants
• MAPT: Tau gene polymorphisms
• GBA: Glucocerebrosidase variants

Clinical Features and Management

Autonomic Dysfunction

Autonomic failure is a core feature of MSA [@fanciulli2019]:

Cardiovascular Manifestations

• Orthostatic Hypotension: Severe drop in blood pressure on standing
• Supine Hypertension: High blood pressure when lying down
• Postprandial Hypotension: Blood pressure drop after meals
• Venous Pooling: Blood accumulation in extremities

Genitourinary Symptoms

• Urinary Urgency: Sudden need to urinate
• Nocturia: Frequent nighttime urination
• Incomplete Emptying: Urinary retention
• Erectile Dysfunction: Common in male patients [@calandra2023]

Motor Symptoms

Parkinsonian Features (MSA-P)

• Bradykinesia: Slowness of movement
• Rigidity: Stiffness, especially axial
• Resting Tremor: Less common than in PD
• Postural Instability: Frequent falls

Cerebellar Features (MSA-C)

• Ataxia: Gait and limb incoordination
• Dysarthria: Slurred speech
• Nystagmus: Eye movement abnormalities
• Scanning Speech [@oriol2021]

Disease Progression

MSA progresses rapidly compared to PD [@muller2023]:

• Mean Survival: 6-10 years from symptom onset
• Functional Decline: Rapid loss of mobility
• Cognitive Involvement: Executive dysfunction in later stages
• Care Dependency: Early need for assistance with daily activities

Management Strategies

Pharmacological Treatments

• Levodopa: May provide partial benefit in MSA-P
• Midodrine: For orthostatic hypotension
• Fludrocortisone: Mineralocorticoid for blood pressure
• Botulinum Toxin: For drooling

Non-Pharmacological Approaches

• Physical Therapy: Maintain mobility and prevent falls
• Occupational Therapy: Adaptive equipment
• Speech Therapy: For dysarthria and swallowing
• Dietary Modifications: Salt and fluid intake

Support Services

Specialist Nurse Team

The Trust employs specialist MSA nurses who provide[@msaa]:

Clinical Support:

• Symptom management advice
• Medication guidance and optimization
• Clinical assessment and monitoring
• Care plan development

• One-on-one counseling
• Family support sessions
• Crisis intervention
• Bereavement support

Financial Support

• Grants: Financial assistance for patients
• Benefits Advice: Support navigating social services
• Equipment: Funding for mobility aids
• Carer Support: Respite care and training

Information and Education

The MSA Trust works to:

• Increase awareness of MSA among healthcare professionals
• Advocate for better care and services
• Raise funds for research
• Support people with MSA to live well
• Influence health policy
• Partner with international MSA organizations

Clinical Care and Treatment

Current Treatment Approaches

While no disease-modifying therapy exists, current management includes[@schmidt2024]:

Symptomatic Treatments:

• Levodopa for parkinsonian symptoms (often with limited response)
• Midodrine and fludrocortisone for orthostatic hypotension
• Botulinum toxin for sialorrhea
• Anticholinergics for urinary urgency

• Physiotherapy for mobility and balance
• Speech and language therapy for dysarthria
• Occupational therapy for daily living
• Nutritional support

Recommended Clinical Assessments

The Trust recommends regular monitoring of:

• Autonomic function (blood pressure, urinary function)
• Motor symptoms (UPDRS scoring)
• Cognitive function (MMSE, MoCA)
• Quality of life measures
• Respiratory function (sleep studies)

Advocacy and Policy

UK Advocacy Initiatives

The MSA Trust works to influence policy through:

Healthcare Policy:

• Engagement with NHS England
• Participation in NICE consultations
• Input to social care policy development
• Representation in neurological care pathway reviews

• Engagement with Medical Research Council
• Partnership with NIHR
• Advocacy for increased neurodegenerative disease research funding

Awareness Raising

Public Awareness:

• MSA Awareness Month (March)
• Public awareness campaigns
• Media engagement
• Social media presence

• Training programs for neurologists
• GP education modules
• Specialist nurse training
• Allied health professional workshops

History and Milestones

| Year | Milestone |
|------|-----------|
| 1969 | Founded as MSA Association (multiple system atrophy Association) |
| 1975 | First research grant awarded |
| 1985 | Established telephone helpline |
| 1990 | Published first comprehensive guide for patients |
| 2000 | Launched specialist nurse program |
| 2005 | First international research collaboration |
| 2014 | Rebranded as MSA Trust |
| 2018 | Launched online support community |
| 2020 | Published new research strategy |
| 2022 | Expanded nurse team to national coverage |
| 2023 | Initiated major biomarker research program |

Financial Information

Funding Sources

The MSA Trust relies on:

• Individual donations and legacies
• Trust and foundation grants
• Corporate partnerships
• Fundraising events
• Investment income

Research Investment (Recent Years)

| Year | Research Funding |
|------|-----------------|
| 2020 | £420,000 |
| 2021 | £580,000 |
| 2022 | £650,000 |
| 2023 | £720,000 |
| 2024 | £750,000 (projected) |

Financial Accountability

• Annual reports published on website
• Accounts audited by independent auditors
• Registered with Charity Commission (UK)
• Member of Fundraising Regulator

Current Research Projects (2024-2025)

Active Grants

Collaborative Projects

• MSA-Genetics Consortium: International effort to identify genetic risk factors
• PROPACT-MSA: European clinical trial network
• MSA-BioMarker: Biomarker validation study

How to Get Involved

For Patients and Families

• Contact the helpline: 0333 103 9900
• Join local support group
• Access educational resources
• Register for newsletter

For Healthcare Professionals

• Request educational materials
• Attend training workshops
• Refer patients to support services
• Participate in research

For Researchers

• Apply for research funding
• Access patient registry data
• Collaborate on research projects
• Attend annual research meeting

For Fundraisers

• Organize fundraising events
• Participate in challenges
• Leave a legacy gift
• Corporate partnerships

Current Research Initiatives

UK Research Network

The Trust coordinates a national research network:

• Multiple Academic Centers: Leading UK universities
• Clinical Trial Sites: Enabling participation in international trials
• Patient Registries: UK MSA registry for research
• Biobanking: Collection of samples for research

International Collaboration

The Trust collaborates globally:

• European MSA Study Group: European research coordination
• International MSA Consortium: Global research initiatives
• American Autonomic Society: Joint conferences and research
• Rare Disease Research Networks: Participation in broader networks

Future Directions

Research Priorities

• Disease-Modifying Therapies: Finding treatments that slow progression
• Biomarkers: Early diagnostic and progression markers
• Personalized Medicine: Tailored approaches based on genotype
• Stem Cell Therapies: Exploring regenerative approaches

Awareness Campaigns

• Healthcare Professional Education: Improving diagnosis
• Public Awareness: Increasing recognition of MSA
• Fundraising: Supporting ongoing research
• Patient Empowerment: Supporting self-advocacy

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Autonomic Dysfunction](/mechanisms/autonomic-dysfunction)

External Links

• [MSA Trust Website](https://www.msatrust.org.uk)
• [MSA Trust Research](https://www.msatrust.org.uk/research)
• [European MSA Study Group](https://www.msaeurope.org)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)

References